

# PRODUCT INFORMATION



## Amiloride (hydrochloride) (hydrate)

Item No. 14409

**Formal Name:** 3,5-diamino-N-(aminoiminomethyl)-6-chloro-2-pyrazinocarboxamide, monohydrochloride hydrate

**Synonym:** MK-870

**MF:** C<sub>6</sub>H<sub>8</sub>ClN<sub>7</sub>O • HCl [XH<sub>2</sub>O]

**FW:** 266.1


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 215, 287, 362 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Amiloride (hydrochloride) (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the amiloride (hydrochloride) (hydrate) in the solvent of choice, which should be purged with an inert gas. Amiloride (hydrochloride) (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of amiloride (hydrochloride) (hydrate) in these solvents is approximately 30 mg/ml.

Amiloride (hydrochloride) (hydrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, amiloride (hydrochloride) (hydrate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Amiloride (hydrochloride) (hydrate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Amiloride is a potassium-sparing diuretic.<sup>1,2</sup> It is an inhibitor of the epithelial sodium channel (ENaC; K<sub>0.5</sub> = 2.6 μM for recombinant δENaC expressed in *X. laevis* oocytes).<sup>3</sup> It inhibits sodium transport from bovine kidney cortex membrane vesicles with an IC<sub>50</sub> value of 0.4 μM.<sup>4</sup> Amiloride inhibits the urokinase-type plasminogen activator (u-PA; K<sub>i</sub> = 7 μM) and cardiac Na<sup>+</sup>/H<sup>+</sup>-ATPase (IC<sub>50</sub> = 83.8 μM).<sup>5,6</sup> It also inhibits calcium currents mediated by transient receptor potential polycystin 3 (TRPP3; IC<sub>50</sub> = 143 μM).<sup>7</sup> Amiloride (30 mg/kg) reduces mean arterial pressure in spontaneously hypertensive, but not normotensive, rats.<sup>8</sup> Formulations containing amiloride have been used alone, and in combination with thiazide diuretics, in the treatment of hypertension.

### References

1. Lingueglia, E., Voilley, N., Lazdunski, M., *et al. Exp. Physiol.* **81**, 483-492 (1996).
2. Qadri, Y.J., Rooj, A.K., and Fuller, C.M. *Am. J. Physiol. Cell Physiol.* **302(7)**, C943-C965 (2012).
3. Waldmann, R., Champigny, G., Bassilana, F., *et al. J. Biol. Chem.* **270(46)**, 27411-27414 (1995).
4. Kleyman, T.R., Yulo, T., Ashbaugh, C., *et al. J. Biol. Chem.* **261(6)**, 2839-2843 (1986).
5. Vassalli, J.D., and Belin, D. *FEBS Lett.* **214(1)**, 187-191 (1987).
6. Kleyman, T.R. and Cragoe, E.J., Jr. *J. Membr. Biol.* **105(1)**, 1-21 (1988).
7. Dai, X.Q., Ramji, A., Liu, Y., *et al. Mol. Pharmacol.* **72(6)**, 1576-1585 (2007).
8. Barrett, R.J. and Kau, S.T. *J. Pharmacol. Exp. Ther.* **239(2)**, 365-374 (1986).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM